Kawasaki disease (KD) is a systemic vasculitis that affects mainly children younger than 5 years.
1-3 It is characterized by a prolonged fever that is unresponsive to antibiotics; a polymorphous rash; erythema of the oral mucosa, lips, tongue, palms, and soles; bilateral conjunctival injection; and cervical lymphadenopathy. Kawasaki disease is often complicated by coronary artery abnormalities (CAAs), and approximately 15% to 25% of untreated children develop coronary artery aneurysms.
1,4 Kawasaki disease is currently the most common cause of pediatric-acquired heart disease in developed countries.
1,5 The primary goal of treatment for the acute phase of KD is to rapidly inhibit the acute-phase systemic inflammatory response in affected patients and successfully prevent the development of CAAs.